Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
Tectonic Therapeutic: A $1B+ Opportunity Hinges On Upcoming Phase 2
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $81.50 Consensus Price Target from Analysts
Aberdeen Group plc Acquires 785,648 Shares of Tectonic Therapeutic, Inc. $TECX
Tectonic Therapeutic, Inc. $TECX Shares Sold by Ally Bridge Group NY LLC
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Tectonic Therapeutic, Inc. (TECX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
Tiziana Life Sciences (NASDAQ:TLSA) vs. Tectonic Therapeutic (NASDAQ:TECX) Financial Comparison
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $82.17 Average Target Price from Brokerages
Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point
Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients Transcript
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
Tectonic Therapeutic to Participate in September Investor Conferences
Tectonic (TECX) Q2 R&D Soars 142%
Tectonic Therapeutic Joins Russell 3000® Index
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
Tectonic: Expansion Of TX45 Candidate Possible After Positive Interim Data
Tectonic Announces $185 Million Private Placement
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
Tectonic Therapeutic: Protein Engineering Platform For GPCRs
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
Tectonic Therapeutic: Interesting CV Disease Drug Developer
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
TECX Stock Earnings: Tectonic Therapeutic Misses EPS for Q2 2024
Tectonic Therapeutic to Participate in September Investor Conferences
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights